These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24305957)

  • 41. Mechanism of inhibition of the retroviral protease by a Rous sarcoma virus peptide substrate representing the cleavage site between the gag p2 and p10 proteins.
    Cameron CE; Grinde B; Jentoft J; Leis J; Weber IT; Copeland TD; Wlodawer A
    J Biol Chem; 1992 Nov; 267(33):23735-41. PubMed ID: 1331099
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lack of a significant impact of Gag-Protease-mediated HIV-1 replication capacity on clinical parameters in treatment-naive Japanese individuals.
    Sakai K; Chikata T; Brumme ZL; Brumme CJ; Gatanaga H; Oka S; Takiguchi M
    Retrovirology; 2015 Nov; 12():98. PubMed ID: 26585907
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors.
    Urano E; Ablan SD; Mandt R; Pauly GT; Sigano DM; Schneider JP; Martin DE; Nitz TJ; Wild CT; Freed EO
    Antimicrob Agents Chemother; 2016 Jan; 60(1):190-7. PubMed ID: 26482309
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease.
    Pettit SC; Henderson GJ; Schiffer CA; Swanstrom R
    J Virol; 2002 Oct; 76(20):10226-33. PubMed ID: 12239298
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Transient HIV-1 Gag-protease interactions revealed by paramagnetic NMR suggest origins of compensatory drug resistance mutations.
    Deshmukh L; Louis JM; Ghirlando R; Clore GM
    Proc Natl Acad Sci U S A; 2016 Nov; 113(44):12456-12461. PubMed ID: 27791180
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat.
    Margot NA; Gibbs CS; Miller MD
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2345-53. PubMed ID: 20308382
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Translation elongation factor 1-alpha interacts specifically with the human immunodeficiency virus type 1 Gag polyprotein.
    Cimarelli A; Luban J
    J Virol; 1999 Jul; 73(7):5388-401. PubMed ID: 10364286
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of HIV-1 inhibitors targeting the nucleocapsid protein.
    Breuer S; Chang MW; Yuan J; Torbett BE
    J Med Chem; 2012 Jun; 55(11):4968-77. PubMed ID: 22587465
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gag-protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to Protease Inhibitors.
    Codoñer FM; Peña R; Blanch-Lombarte O; Jimenez-Moyano E; Pino M; Vollbrecht T; Clotet B; Martinez-Picado J; Draenert R; Prado JG
    Sci Rep; 2017 Jun; 7(1):3717. PubMed ID: 28623276
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Structural and functional insights into the HIV-1 maturation inhibitor binding pocket.
    Waki K; Durell SR; Soheilian F; Nagashima K; Butler SL; Freed EO
    PLoS Pathog; 2012; 8(11):e1002997. PubMed ID: 23144615
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of linker insertion mutations in the human immunodeficiency virus type 1 gag gene on activation of viral protease expressed in bacteria.
    Luban J; Lee C; Goff SP
    J Virol; 1993 Jun; 67(6):3630-4. PubMed ID: 8497070
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Human Immunodeficiency Virus Gag and protease: partners in resistance.
    Fun A; Wensing AM; Verheyen J; Nijhuis M
    Retrovirology; 2012 Aug; 9():63. PubMed ID: 22867298
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HIV type 1 protease cleavage site mutations and viral fitness: implications for drug susceptibility phenotyping assays.
    Robinson LH; Myers RE; Snowden BW; Tisdale M; Blair ED
    AIDS Res Hum Retroviruses; 2000 Aug; 16(12):1149-56. PubMed ID: 10954890
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A human immunodeficiency virus type 1 protease biosensor assay using bioluminescence resonance energy transfer.
    Hu K; Clément JF; Abrahamyan L; Strebel K; Bouvier M; Kleiman L; Mouland AJ
    J Virol Methods; 2005 Sep; 128(1-2):93-103. PubMed ID: 15951029
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Importance of protease cleavage sites within and flanking human immunodeficiency virus type 1 transframe protein p6* for spatiotemporal regulation of protease activation.
    Ludwig C; Leiherer A; Wagner R
    J Virol; 2008 May; 82(9):4573-84. PubMed ID: 18321978
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HIV-1 protease substrate-groove: Role in substrate recognition and inhibitor resistance.
    Laco GS
    Biochimie; 2015 Nov; 118():90-103. PubMed ID: 26300060
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease.
    Dauber DS; Ziermann R; Parkin N; Maly DJ; Mahrus S; Harris JL; Ellman JA; Petropoulos C; Craik CS
    J Virol; 2002 Feb; 76(3):1359-68. PubMed ID: 11773410
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The HIV-1 late domain-2 S40A polymorphism in antiretroviral (or ART)-exposed individuals influences protease inhibitor susceptibility.
    Watanabe SM; Simon V; Durham ND; Kemp BR; Machihara S; Kemal KS; Shi B; Foley B; Li H; Chen BK; Weiser B; Burger H; Anastos K; Chen C; Carter CA
    Retrovirology; 2016 Sep; 13(1):64. PubMed ID: 27600154
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mutations in multiple domains of Gag drive the emergence of in vitro resistance to the phosphonate-containing HIV-1 protease inhibitor GS-8374.
    Stray KM; Callebaut C; Glass B; Tsai L; Xu L; Müller B; Kräusslich HG; Cihlar T
    J Virol; 2013 Jan; 87(1):454-63. PubMed ID: 23097440
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of amino acid variations in Gag and protease of HIV type 1 CRF01_AE strains on drug susceptibility of virus to protease inhibitors.
    Jinnopat P; Isarangkura-na-ayuthaya P; Utachee P; Kitagawa Y; de Silva UC; Siripanyaphinyo U; Kameoka Y; Tokunaga K; Sawanpanyalert P; Ikuta K; Auwanit W; Kameoka M
    J Acquir Immune Defic Syndr; 2009 Nov; 52(3):320-8. PubMed ID: 19727001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.